Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Omegaven dosing study in high-risk cardiac surgery patients
2016-003902-14Phase 2Completed
- Sponsor
- RWTH Aachen University
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of eicosapentaenoic acid + docosahexaenoic acid in cardiac morbidity (3 arms), sponsored by RWTH Aachen University. Primary endpoint: Safety and efficacy. Started Feb 2017; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on 2016-003902-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003902-14.